Abstract: The present invention provides combinations of (a) an immunoconjugate comprising a first antibody engineered to have reduced effector function and an effector moiety, and (b) a second antibody engineered to have increased effector function, for use in treating a disease in an individual in need thereof. Further provided are pharmaceutical compositions comprising the combinations, and methods of using them.
Type:
Grant
Filed:
August 7, 2013
Date of Patent:
December 27, 2016
Assignee:
Roche Glycart AG
Inventors:
Christian Gerdes, Christian Klein, Valeria G. Nicolini, Pablo Umana
Abstract: The present invention relates to conjugates comprising a peptide of at least 10 amino acid residues comprising the amino acid sequence GITELKKL (residues 383-390 of SEQ ID NO: 3) for induction of potent humoral and cellular immune responses when administered to subjects having antibodies against tetanus toxoid. In one embodiment the invention relates to a prophylactic and therapeutic vaccine and in a further embodiment the invention relates to the treatment or prevention of cancer or an infectious disease.
Type:
Grant
Filed:
March 15, 2011
Date of Patent:
December 20, 2016
Assignees:
Academisch Ziekenhuis Leiden h.o.d.n. LUMC, Stichting voor de Technische Wetenschappen
Inventors:
Ferdinand Antonius Ossendorp, Cornelis Joseph Maria Melief, Jan Wouter Drijfhout
Abstract: Specific binding members, particularly antibodies and fragments thereof, which bind to transforming growth factor beta 1 (TGF-?1) are provided, particularly recognizing human and mouse TGF-?1 and not recognizing or binding TGF-?2 or TGF-?3. Particular antibodies are provided which specifically recognize and neutralize TGF-?1. These antibodies are useful in the diagnosis and treatment of conditions associated with activated or elevated TGF-?1, including cancer, and for modulating immune cells and immune response, including immune response to cancer or cancer antigens. The anti-TGF-?1 antibodies, variable regions or CDR domain sequences thereof, and fragments thereof may also be used in therapy in combination with chemotherapeutics, immune modulators, or anti-cancer agents and/or with other antibodies or fragments thereof. Antibodies of this type are exemplified by the novel antibodies hereof, including antibody 13A1, whose sequences are provided herein.
Type:
Grant
Filed:
March 6, 2013
Date of Patent:
December 13, 2016
Assignee:
Ludwig Institute for Cancer Research LTD
Inventors:
Jacques Van Snick, Catherine Uyttenhove, Thierry Boon
Abstract: An anti-human-CC-motif-receptor-7 (anti-human-CCR7) antibody which is useful as a therapeutic agent for tissue fibrosis or cancer, and a pharmaceutical composition containing the anti-human CCR7 antibody, and the like is described. An anti-human CCR7 antibody specifically binding to an extracellular domain of human CCR7, having a heavy chain CDR3 containing an amino acid sequence represented by SEQ ID NO: 7, SEQ ID NO: 17, SEQ ID NO: 27, SEQ ID NO: 37, SEQ ID NO: 47, SEQ ID NO: 57, SEQ ID NO: 67, or SEQ ID NO: 77 is provided. Also provided is an anti-human CCR7 antibody having heavy chain CDRs 1-3 and light chain CDRs 1-3 containing amino acid sequences represented by SEQ ID NOs: 5-10, 15-20, 25-30, 35-40, 45-50, 55-60, 65-70, or 75-80. The anti-human CCR7 antibody of the present invention may be used as an active ingredient of a therapeutic agent for tissue fibrosis or cancer.
Type:
Grant
Filed:
September 18, 2014
Date of Patent:
November 29, 2016
Assignees:
SEKISUI CHEMICAL CO., LTD., NB HEALTH LABORATORY CO., LTD.
Abstract: This invention describes novel adjuvant compositions and formulations with excellent stability at refrigerated and room temperatures and up to and about 37° C. that can be produced at remarkably low costs. This invention describes novel vaccine compositions and formulations to treat and prevent urinary tract infections caused by gram-negative bacteria including Escherichia coli and multi-drug resistant E. coli. This invention also describes methods of administration of said novel vaccine compositions and formulations and methods of treatment to prevent and treat urinary tract infections caused by gram-negative bacteria including E. coli and multi-drug resistant E. coli.
Abstract: The invention relates to a method for detecting contaminants of glucose polymers, said contaminants being capable of acting in synergy with one another so as to trigger an inflammatory reaction, characterized in that it comprises an in vitro inflammatory response test using modified cell lines.
Type:
Grant
Filed:
April 6, 2012
Date of Patent:
November 15, 2016
Assignee:
ROQUETTE FRERES
Inventors:
Pierre Lanos, Hela Hacine-Gherbi, Fabrice Allain, Mathieu Carpentier, Agnes Denys
Abstract: This invention relates to a novel method for growing attenuated mutant Salmonella typhi strains lacking galactose epimerase activity and harboring a recombinant DNA molecule. The method comprises the step of culturing said Salmonella typhi strain without adding glucose to the medium during the fermentation with a starting glucose amount that is depleted before reaching the stationary phase. The invention further relates to attenuated mutant Salmonella typhi strains obtainable by said method and to an attenuated mutant Salmonella typhi strain harboring a recombinant DNA molecule encoding a VEGF receptor protein for use as a vaccine.
Type:
Grant
Filed:
December 21, 2012
Date of Patent:
November 15, 2016
Assignee:
VAXIMM AG
Inventors:
Heinz Lubenau, Holger Siede, Renate Janssen, Marco Springer
Abstract: The present invention provides a bacillus sp. having a deposit access number of CGMCC NO. 5744 and a hyaluronidase produced by the bacillus and the amino acid sequence of the hyaluronidase is shown in SEQ ID NO: 2. The present invention further relates to a process for preparing oligomeric hyaluronic acid or salts thereof or low-molecular-weight hyaluronic acid or salts thereof by using the bacillus or the hyaluronidase produced thereby. The produced oligomeric hyaluronates or low-molecular-weight hyaluronates have advantages such as good transdermal absorption ability, high purity, no cytotoxicity, potent antioxidant ability. The present invention also provides use of the bacillus having a deposit access number of CGMCC NO. 5744, or the hyaluronidase, oligomeric hyaluronates or salts thereof, low-molecular-weight hyaluronates or salts thereof produced by the bacillus in the fields of osmetics, food products and medicines.
Abstract: This invention describes novel adjuvant compositions and formulations with excellent stability at refrigerated and room temperatures and up to and about 37° C. that can be produced at remarkably low costs. This invention describes novel vaccine compositions and formulations to treat and prevent urinary tract infections caused by gram-negative bacteria including Escherichia coli and multi-drug resistant E. coli. This invention also describes methods of administration of said novel vaccine compositions and formulations and methods of treatment to prevent and treat urinary tract infections caused by gram-negative bacteria including E. coli and multi-drug resistant E. coli.
Abstract: The present invention refers to a combination of growth factors, cytokines, antibacterial/antiviral factors, stem cell stimulating factors, complement proteins C3a/C4a, and chemotactic factors. The invention also relates to a process for the preparation of said combination from serum, placenta or colostrum and to composition containing said combination for use in the treatment of conditions requiring tissue repair and regeneration and for the substitution of stem cell therapies.
Abstract: The present invention provides Listeria vaccine strains that express a heterologous antigen and a metabolic enzyme, and methods of generating same.
Type:
Grant
Filed:
November 10, 2014
Date of Patent:
November 15, 2016
Assignee:
THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA
Abstract: The present invention is directed to a monoclonal antibody that binds specifically to a Staphylococcus aureus glucosaminidase and inhibits in vivo growth of S. aureus. Also disclosed are monoclonal antibody binding portions, recombinant or hybridoma cell lines, pharmaceutical compositions containing the monoclonal antibody or binding portions thereof, and methods of treating S. aureus infection and osteomyelitis, and methods for introducing an orthopedic implant into a patient using the monoclonal antibody, binding portion, or pharmaceutical composition of the present invention.
Type:
Grant
Filed:
October 30, 2012
Date of Patent:
November 8, 2016
Assignee:
University of Rochester
Inventors:
Edward M. Schwarz, Mark A. Sullivan, John L. Daiss
Abstract: The present invention is related to a pharmaceutical formulation comprising a biopharmaceutical drug, said composition further comprising at least one mono- or dicarboxylic acid with a backbone of 2-6 C-Atoms, or at least one salt thereof.
Abstract: Establishment of an effective and uniform vaccine development strategy is key to conquering current and emerging infectious diseases. Despite successes against an array of bacterial agents, current approaches to vaccine development are as diverse as the microbes they target and require adjuvants that often have limited efficacy and/or toxic side effects. As a consequence, vaccine discovery is often slow, inefficient, and unsuccessful in the case of many high priority pathogens. The present disclosure suggests that vaccine generation for bacterial pathogens can be improved by optimizing the efficiency of processing/presentation of a bacterial immunogen via the targeting of immunogen to CR2 and/or TLR2 on APCs. This approach not only yields an adjuvant-free mucosal vaccine against a Category A biothreat agent, but also establishes a novel genetic approach/platform for vaccine development, which is applicable to many other infectious agents, thereby profoundly impacting preventive medicine/public health.
Type:
Grant
Filed:
January 22, 2013
Date of Patent:
October 25, 2016
Assignee:
ALBANY MEDICAL COLLEGE
Inventors:
Karsten Hazlett, Edmund Gosselin, Timothy Sellati, Tiffany Zarrella
Abstract: The invention relates to a composition comprising a glycoprotein comprising the Fc domain of an antibody, or a fragment thereof, comprising an Asn (asparagine) residue and an oligosaccharide structure attached thereto, wherein said oligosaccharide structure has a structure according to formula I; and wherein at least 20% of the oligosaccharide structures attached to glycoprotein in the composition consist of oligosaccharide structures according to formula (I).
Type:
Grant
Filed:
December 13, 2012
Date of Patent:
October 11, 2016
Assignee:
Glykos Finland Oy
Inventors:
Tero Satomaa, Juhani Saarinen, Jari Natunen, Anja Vilkman, Heidi Virtanen, Jukka Hiltunen
Abstract: Methods are described for producing enteroendocrine cells that make and secrete insulin in a mammal by blocking the expression or biological activity of one or more Foxo proteins or biologically active fragments or variants thereof.
Type:
Grant
Filed:
May 12, 2011
Date of Patent:
October 4, 2016
Assignee:
The Trustees Of Columbia University In The City Of New York
Abstract: Methods for prolongation of climax time in a patient in need thereof are presented, as are methods for treating premature ejaculation by local administration of a Clostridial neurotoxin, such as botulinum neurotoxin, to the patient, are provided.
Type:
Grant
Filed:
November 16, 2015
Date of Patent:
October 4, 2016
Assignee:
Allergan, Inc.
Inventors:
Ivan Aguilar, Gustavo M. Gaxiola, Gilberto P. Paz
Abstract: A method and system for targeting the microbiome to promote health involves exposing an expectant mother to a mixture of farm derived manure-containing soil to reduce the chances her baby will suffer allergies and autoimmune diseases. City dwelling expectant mothers are exposed to immunologic agents and allergens in a fashion (e.g., via exposure to farm animal manure-containing soils) that charges their immune system and that of their fetus(es) so that their babies, once born, are provided with immunity against a variety of autoimmune diseases, including allergies commonly and increasingly experienced in modern urban environments.
Type:
Grant
Filed:
November 30, 2015
Date of Patent:
October 4, 2016
Inventors:
Katherine Rose Kovarik, Joseph E. Kovarik
Abstract: Antigen binding proteins with TCR-like paratopes, that is, with an antigen binding region specific for an HLA-A2 restricted peptide are disclosed. The antigen binding proteins encompass antibodies in a variety of forms, including full-length antibodies, substantially intact antibodies, Fab fragments, F(ab?)2 fragments, and single chain Fv fragments. Fusion proteins, such as scFv fusions with immunoglobulin or T-cell receptor domains, incorporating the specificity of the antigen binding region for each peptide are also contemplated by the invention. Furthermore, immunoconjugates may include antibodies to which is linked a radioisotope, fluorescent or other detectable marker, cytotoxin, or other molecule are also encompassed by the invention. Among other things, immunoconjugates can be used for delivery of an agent to elicit a therapeutic effect or to facilitate an immune effector function.
Type:
Grant
Filed:
June 9, 2014
Date of Patent:
September 27, 2016
Assignee:
MEMORIAL SLOAN-KETTERING CANCER CENTER
Inventors:
Nai-Kong Cheung, Dimiter Tassev, Jian Hu
Abstract: A process of purifying the Growth Factor Protein G-CSF (Granulocyte Colony Stimulating Factor) in a purification sequence employing chromatography, comprising binding the G-CSF to Capto MMC™, which is a multimodal resin that comprises a negatively charged 2-(benzoylamino) butanoic acid ligand, at a pH from 4 to 6.2; and eluting the G-CSF at a pH greater than 6.3.
Type:
Grant
Filed:
March 30, 2011
Date of Patent:
September 27, 2016
Assignee:
OCTAPHARMA AG
Inventors:
Gustav Gilljam, Stefan Winge, Maya Tiemeyer